The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00IYVI     (methyl-(2- phenylsulfanylethyl) phosphoryl)...

Synonyms: AG-J-64161, NSC-633097, CTK7B4415, NSC633096, NSC633097, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AIDS160500

  • PURPOSE: Our purpose was to compare, on a pharmacokinetic, biological, and clinical basis, the racemic mixture d,l-FA with the pure l-FA in rescue of high-dose MTX therapy (5 g/m2) in children with acute lymphocytic leukemia (ALL) [1].
  • The (+) and (-) isomers of the above racemic mixture did not differ significantly in their capacity to inhibit phage replication [2].
  • It is administered clinically as a racemic mixture, but only one enantiomer is active (eutomer) while the other (distomer) has been implicated in causing toxicity [3].
  • The subsequently determined crystal structure with HIV-1 protease, cocrystallized from a racemic mixture, exclusively reveals the S,R,S-enantiomer accommodated to the binding pocket [4].
  • Beginning with a cocrystal structure of a Phe-Pro peptidomimetic bound to the HIV Pr, design was initiated that resulted in the substituted 2-butanol compound 8 as the lead compound (Ki = 24.5 microM, racemic mixture) [5].

Psychiatry related information on AIDS160500

  • Even though the apparent anaesthetic state produced in these healthy volunteers did not differ qualitatively between the three drug groups, recovery times (assessed using a standardized battery of psychometric tests) were consistently shorter following the individual isomers compared with the racemic mixture [6].

High impact information on AIDS160500


Chemical compound and disease context of AIDS160500


Biological context of AIDS160500

  • The results of analysis of the product mixture derived from autoxidation of optically pure Ch-15-HpETE by atmospheric pressure chemical ionization-mass spectrometry coupled with chiral high performance liquid chromatography indicate that the major isoprostane diastereomers are formed as a racemic mixture [17].
  • Substituting a racemic mixture of the beta-amino acid isoserine for serine in a related peptide ligand (SFLLRN) produced an active peptide ((iso-S)FLLRN) that is approximately 15-20% as potent as SFLLRN as judged by platelet aggregation [18].
  • The experimental observation that in the racemic mixture, (2S, 5S)-5-fluoromethylornithine is exclusively responsible for the enzyme inhibition can be explained on the basis of the active site topology [19].
  • The racemic mixture has an IC50 of 11.2 +/- 0.5 microM, whereas (S)-HA-966 has an IC50 greater than 900 microM [20].
  • Hybrid silicas with hollow tubular morphologies were obtained by the hydrolysis of the enantiomerically pure compounds, (R,R)-1 or (S,S)-1, whereas the corresponding racemic mixture, rac-1, led to a hybrid with ball-like structures [21].

Anatomical context of AIDS160500


Associations of AIDS160500 with other chemical compounds

  • Single-crystal X-ray diffraction analysis of a racemic mixture of Ru(Zn2L4)3 showed that three of the six Zn2+-cyclen units are orientated to face the opposite side of the molecule with three apical ligands (Zn2+-bound HO-) of each of the three Zn2+ located on the same face [27].
  • Another type of the one-step (S)-isomer biocatalytic preparation from racemic mixture of propranolol is the biodegradation with the fungus [28].
  • In epitrochlearis muscles isolated from obese Zucker rats, insulin (2 mU/ml) significantly (p < 0.05) increased in vitro protein synthesis (phenylalanine incorporation into protein) and decreased net protein degradation (tyrosine release), whereas a racemic mixture of ALA (2 mM) had no effect on either process [29].
  • The most widely used long-acting amide local anaesthetic is bupivacaine, a racemic mixture of 2 stereoisomers [30].
  • This paper describes the labeling of the highly potent serotonin (5-HT) uptake blocker, McN-5652-Z (trans-1,2,3,5,6,10 beta-hexahydro-6-[4-(methylthio)phenyl]pyrrolo-[2,1-a]-isoquinoline; racemic mixture), with 11C and the evaluation of this radiotracer in rodents with respect to its in vivo binding characteristics [31].

Gene context of AIDS160500

  • S-fluoxetine is on average a 5 fold weaker CYP2C9 inhibitor than either R-fluoxetine or the racemic mixture [32].
  • The Ser-->Phe substitution indeed affected the potency and P-gp isoform specificity of some of the modulators, in particular that of CP117227 (racemic mixture and enantiomers), which were active against wild-type but not mutant mdr3 [33].
  • The two enantiomers of the racemic mixture MEPQ inhibited AChE at similar rates [34].
  • 1. We investigated the effects of the non-peptide NK1 receptor antagonist, CP-96,345, its inactive enantiomer CP-96,344, and the racemic mixture (+/-)-CP-96,345, on the binding of [3H]-nimodipine and [3H]-diltiazem to L-type calcium channels in rat cerebral cortex membranes [35].
  • The new analogues comprise the four possible stereoisomers of 1-amino-1-carboxycyclopentane-3-acetic acid (1,3-homo-ACPD) and the racemic mixture of (1RS,2RS)-1-amino-1-carboxycyclopentane-2-acetic acid (1RS,2RS-homo-ACPD), (1RS,2RS)-Homo-ACPD was shown to be a competitive mGlu2 receptor antagonist with a KB of 391 microM [36].

Analytical, diagnostic and therapeutic context of AIDS160500


  1. l-folinic acid versus d,l-folinic acid in rescue of high-dose methotrexate therapy in children. Etienne, M.C., Thyss, A., Bertrand, Y., Touraine, R., Rubie, H., Robert, A., Milano, G. J. Natl. Cancer Inst. (1992) [Pubmed]
  2. A bacteriophage system for screening and study of biologically active polycyclic aromatic hydrocarbons and related compounds. Hsu, W.T., Harvey, R.G., Lin, E.J., Weiss, S.B. Proc. Natl. Acad. Sci. U.S.A. (1977) [Pubmed]
  3. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Boulton, D.W., Fawcett, J.P. Clin. Pharmacol. Ther. (1997) [Pubmed]
  4. Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization. Specker, E., Böttcher, J., Heine, A., Sotriffer, C.A., Lilie, H., Schoop, A., Müller, G., Griebenow, N., Klebe, G. J. Med. Chem. (2005) [Pubmed]
  5. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. Reich, S.H., Melnick, M., Pino, M.J., Fuhry, M.A., Trippe, A.J., Appelt, K., Davies, J.F., Wu, B.W., Musick, L. J. Med. Chem. (1996) [Pubmed]
  6. Comparative pharmacology of the ketamine isomers. Studies in volunteers. White, P.F., Schüttler, J., Shafer, A., Stanski, D.R., Horai, Y., Trevor, A.J. British journal of anaesthesia. (1985) [Pubmed]
  7. Chiral recognition in dimerization of adsorbed cysteine observed by scanning tunnelling microscopy. Kühnle, A., Linderoth, T.R., Hammer, B., Besenbacher, F. Nature (2002) [Pubmed]
  8. Bispecific Abs against modified protein and DNA with oxidized lipids. Akagawa, M., Ito, S., Toyoda, K., Ishii, Y., Tatsuda, E., Shibata, T., Yamaguchi, S., Kawai, Y., Ishino, K., Kishi, Y., Adachi, T., Tsubata, T., Takasaki, Y., Hattori, N., Matsuda, T., Uchida, K. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  9. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Pollick, C., Giacomini, K.M., Blaschke, T.F., Nelson, W.L., Turner-Tamiyasu, K., Briskin, V., Popp, R.L. Circulation (1982) [Pubmed]
  10. Do N-methyl-D-aspartate receptors mediate synaptic responses in the mudpuppy retina? Coleman, P.A., Miller, R.F. J. Neurosci. (1988) [Pubmed]
  11. A novel insulin-releasing substance, phanoside, from the plant Gynostemma pentaphyllum. Norberg, A., Hoa, N.K., Liepinsh, E., Van Phan, D., Thuan, N.D., Jörnvall, H., Sillard, R., Ostenson, C.G. J. Biol. Chem. (2004) [Pubmed]
  12. Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. Herzmann, C., Arastèh, K., Murphy, R.L., Schulbin, H., Kreckel, P., Drauz, D., Schinazi, R.F., Beard, A., Cartee, L., Otto, M.J. Antimicrob. Agents Chemother. (2005) [Pubmed]
  13. Growth and end product formation of two psychrotrophic Lactobacillus spp. and Brochothrix thermosphacta ATCC 11509T at different pH values and temperatures. Blickstad, E. Appl. Environ. Microbiol. (1983) [Pubmed]
  14. Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol. Lin, T.S., Schinazi, R.F., Zhu, J., Birks, E., Carbone, R., Si, Y., Wu, K., Huang, L., Prusoff, W.H. Biochem. Pharmacol. (1993) [Pubmed]
  15. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Sten, T., Qvisen, S., Uutela, P., Luukkanen, L., Kostiainen, R., Finel, M. Drug Metab. Dispos. (2006) [Pubmed]
  16. Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. von Deutsch, D.A., Abukhalaf, I.K., Wineski, L.E., Aboul-Enein, H.Y., Pitts, S.A., Parks, B.A., Oster, R.A., Paulsen, D.F., Potter, D.E. Chirality. (2000) [Pubmed]
  17. Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid. "Dioxetane" intermediate versus beta-fragmentation of peroxyl radicals. Yin, H., Havrilla, C.M., Gao, L., Morrow, J.D., Porter, N.A. J. Biol. Chem. (2003) [Pubmed]
  18. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. Coller, B.S., Springer, K.T., Scudder, L.E., Kutok, J.L., Ceruso, M., Prestwich, G.D. J. Biol. Chem. (1993) [Pubmed]
  19. Crystal structure of human ornithine aminotransferase complexed with the highly specific and potent inhibitor 5-fluoromethylornithine. Storici, P., Capitani, G., Müller, R., Schirmer, T., Jansonius, J.N. J. Mol. Biol. (1999) [Pubmed]
  20. Stereoselectivity for the (R)-enantiomer of HA-966 (1-hydroxy-3-aminopyrrolidone-2) at the glycine site of the N-methyl-D-aspartate receptor complex. Pullan, L.M., Britt, M., Chapdelaine, M.J., Keith, R.A., LaMonte, D., Mangano, T.J., Patel, J., Powel, R.J., Stumpo, R.J., Warwick, P.J. J. Neurochem. (1990) [Pubmed]
  21. Shape-controlled bridged silsesquioxanes: hollow tubes and spheres. Moreau, J.J., Vellutini, L., Wong Chi Man, M., Bied, C. Chemistry (Weinheim an der Bergstrasse, Germany) (2003) [Pubmed]
  22. Direct effects of platelet-activating factor on isolated rat osteoclasts. Rapid elevation of intracellular free calcium and transient retraction of pseudopods. Wood, D.A., Hapak, L.K., Sims, S.M., Dixon, S.J. J. Biol. Chem. (1991) [Pubmed]
  23. Effects of maternal diabetes on early embryogenesis. Alterations in morphogenesis produced by the ketone body, B-hydroxybutyrate. Horton, W.E., Sadler, T.W. Diabetes (1983) [Pubmed]
  24. Production in vitro by the cytochrome P450 CYP94A1 of major C18 cutin monomers and potential messengers in plant-pathogen interactions: enantioselectivity studies. Pinot, F., Benveniste, I., Salaün, J.P., Loreau, O., Noël, J.P., Schreiber, L., Durst, F. Biochem. J. (1999) [Pubmed]
  25. Enantiospecific syntheses of alpha-(fluoromethyl)tryptophan analogues: interactions with tryptophan hydroxylase and aromatic L-amino acid decarboxylase. Zembower, D.E., Gilbert, J.A., Ames, M.M. J. Med. Chem. (1993) [Pubmed]
  26. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Corsini, A., Mazzotti, M., Raiteri, M., Soma, M.R., Gabbiani, G., Fumagalli, R., Paoletti, R. Atherosclerosis (1993) [Pubmed]
  27. A luminescence sensor of inositol 1,4,5-triphosphate and its model compound by ruthenium-templated assembly of a bis(Zn2+-cyclen) complex having a 2,2'-bipyridyl linker (cyclen = 1,4,7,10-tetraazacyclododecane). Aoki, S., Zulkefeli, M., Shiro, M., Kohsako, M., Takeda, K., Kimura, E. J. Am. Chem. Soc. (2005) [Pubmed]
  28. Biocatalytic approaches to optically active beta-blockers. Zelaszczyk, D., Kieć-Kononowicz, K. Current medicinal chemistry (2007) [Pubmed]
  29. Antioxidant alpha-lipoic acid and protein turnover in insulin-resistant rat muscle. Weinstein, R.B., Tritschler, H.J., Henriksen, E.J. Free Radic. Biol. Med. (2001) [Pubmed]
  30. Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions. Thomas, J.M., Schug, S.A. Clinical pharmacokinetics. (1999) [Pubmed]
  31. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. Suehiro, M., Scheffel, U., Dannals, R.F., Ravert, H.T., Ricaurte, G.A., Wagner, H.N. J. Nucl. Med. (1993) [Pubmed]
  32. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Schmider, J., Greenblatt, D.J., von Moltke, L.L., Karsov, D., Shader, R.I. British journal of clinical pharmacology. (1997) [Pubmed]
  33. Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Kajiji, S., Dreslin, J.A., Grizzuti, K., Gros, P. Biochemistry (1994) [Pubmed]
  34. Synthesis and in vitro properties of a powerful quaternary methylphosphonate inhibitor of acetylcholinesterase. A new marker in blood-brain barrier research. Levy, D., Ashani, Y. Biochem. Pharmacol. (1986) [Pubmed]
  35. The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences. Guard, S., Boyle, S.J., Tang, K.W., Watling, K.J., McKnight, A.T., Woodruff, G.N. Br. J. Pharmacol. (1993) [Pubmed]
  36. New analogues of ACPD with selective activity for group II metabotropic glutamate receptors. Bräuner-Osborne, H., Madsen, U., Mikiciuk-Olasik, E., Curry, K. Eur. J. Pharmacol. (1997) [Pubmed]
  37. Probing helix propensity of monomers within a helical oligomer. Dolain, C., Léger, J.M., Delsuc, N., Gornitzka, H., Huc, I. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  38. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes. Valenzuela, C., Snyders, D.J., Bennett, P.B., Tamargo, J., Hondeghem, L.M. Circulation (1995) [Pubmed]
  39. 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Fohr, I.P., Prinz-Langenohl, R., Brönstrup, A., Bohlmann, A.M., Nau, H., Berthold, H.K., Pietrzik, K. Am. J. Clin. Nutr. (2002) [Pubmed]
  40. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. Lubberink, M., Luurtsema, G., van Berckel, B.N., Boellaard, R., Toornvliet, R., Windhorst, A.D., Franssen, E.J., Lammertsma, A.A. J. Cereb. Blood Flow Metab. (2007) [Pubmed]
  41. Synthesis of high specific activity (+)- and (-)-6-[18F]fluoronorepinephrine via the nucleophilic aromatic substitution reaction. Ding, Y.S., Fowler, J.S., Gatley, S.J., Dewey, S.L., Wolf, A.P. J. Med. Chem. (1991) [Pubmed]
WikiGenes - Universities